Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(Commission File Number)
|
(State or other jurisdiction of incorporation) |
(I.R.S. Employer Identification No.) |
|
|
| |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 1.01 | Entry into a Material Definitive Agreement. |
On November 13, 2025, Fennec Pharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and Craig-Hallum Capital Group LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 4,666,667 common shares, no par value (the “Shares”), to the Underwriters (the “Offering”). The Shares are to be sold at a public offering price of $7.50 per share, and will be purchased by the Underwriters from the Company at a price of $6.975 per Share. The Company also granted the Underwriters a 30-day option to purchase up to an additional 700,000 Shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on November 17, 2025, subject to the satisfaction of customary closing conditions.
The Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-275452), which was previously filed with the Securities Exchange Commission on November 9, 2023 and declared effective on December 15, 2023.
A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations of the Company and the Underwriters. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to the Underwriting Agreement. The foregoing descriptions of the Underwriting Agreement do not purport to be complete and are qualified in their entirety by reference to such exhibits. The provisions of the Underwriting Agreement, including any representations and warranties contained therein, are not for the benefit of any party other than the parties to the Underwriting Agreement and are not intended for investors and the public to obtain factual information about the current state of affairs of the parties. Rather, for information about the Company, investors and the public should look to disclosures contained in the Company’s reports under the Securities Exchange Act of 1934, as amended.
A copy of the opinion of LaBarge Weinstein LLP relating to the validity of the Shares issued in the Offering is filed herewith as Exhibit 5.1.
| Item 8.01 | Other Events. |
The full text of the press release announcing the proposed underwritten public offering on November 13, 2025 and the full text of the press release announcing the pricing of the underwritten public offering on November 13, 2025 are attached as Exhibits 99.1 and 99.2 hereto and are incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit No. | Description |
| Exhibit 1.1 | Underwriting Agreement, dated November 13, 2025, by and among the Company and Piper Sandler & Co. and Craig-Hallum Capital Group LLC, as representatives of the several underwriters named therein |
| Exhibit 5.1 | Opinion of LaBarge Weinstein LLP |
| Exhibit 23.1 | Consent of LaBarge Weinstein LLP (included in Exhibit 5.1) |
| Exhibit 99.1 | Press Release dated November 13, 2025 |
| Exhibit 99.2 | Press Release dated November 13, 2025 |
| Exhibit 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| FENNEC PHARMACEUTICALS INC. | ||
| Date: November 17, 2025 | By: | /s/ Jeff Hackman |
| Jeff Hackman Chief Executive Officer |
3